EA200501863A1 - Полимерные производные, имеющие специфические атомные структуры - Google Patents

Полимерные производные, имеющие специфические атомные структуры

Info

Publication number
EA200501863A1
EA200501863A1 EA200501863A EA200501863A EA200501863A1 EA 200501863 A1 EA200501863 A1 EA 200501863A1 EA 200501863 A EA200501863 A EA 200501863A EA 200501863 A EA200501863 A EA 200501863A EA 200501863 A1 EA200501863 A1 EA 200501863A1
Authority
EA
Eurasian Patent Office
Prior art keywords
specific nuclear
polymeric derivatives
nuclear structures
polymeric reagents
polymeric
Prior art date
Application number
EA200501863A
Other languages
English (en)
Other versions
EA011351B1 (ru
Inventor
Дж. Милтон Харрис
Энтони Козловски
Сэмуел П. МакМанус
Майкл Д. Бентли
Стивен А. Чарлз
Original Assignee
Нектар Терапеутикс Ал, Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нектар Терапеутикс Ал, Корпорейшн filed Critical Нектар Терапеутикс Ал, Корпорейшн
Publication of EA200501863A1 publication Critical patent/EA200501863A1/ru
Publication of EA011351B1 publication Critical patent/EA011351B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33344—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carbamate group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group
    • C08G65/33337—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group cyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyethers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предлагаются полимерные реагенты, включающие часть атомов, расположенных в определенном порядке, в котором часть расположена между водорастворимым полимером и реактивной группой. Полимерные реагенты являются эффективными, кроме всего прочего, для формирования конъюгатов полимер-активный агент. Также предлагаются родственные способы, составы, препараты и т.д.
EA200501863A 2003-05-23 2004-05-21 Полимерные реагенты, способы их получения, а также содержащие их конъюгаты и фармацевтические препараты EA011351B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47321303P 2003-05-23 2003-05-23
PCT/US2004/016212 WO2005000360A2 (en) 2003-05-23 2004-05-21 Peg derivatives having an amidocarbonate linkage

Publications (2)

Publication Number Publication Date
EA200501863A1 true EA200501863A1 (ru) 2006-06-30
EA011351B1 EA011351B1 (ru) 2009-02-27

Family

ID=33551443

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501863A EA011351B1 (ru) 2003-05-23 2004-05-21 Полимерные реагенты, способы их получения, а также содержащие их конъюгаты и фармацевтические препараты

Country Status (22)

Country Link
US (1) US7887789B2 (ru)
EP (3) EP1626741A2 (ru)
JP (1) JP5048332B2 (ru)
KR (1) KR101128320B1 (ru)
CN (1) CN1747748B (ru)
AU (1) AU2004251602B2 (ru)
CA (1) CA2510040C (ru)
CY (1) CY1121759T1 (ru)
DK (1) DK2644206T3 (ru)
EA (1) EA011351B1 (ru)
ES (1) ES2725808T3 (ru)
HU (1) HUE043911T2 (ru)
IL (1) IL169165A (ru)
LT (1) LT2644206T (ru)
MX (1) MXPA05007628A (ru)
NZ (1) NZ541374A (ru)
PL (1) PL2644206T3 (ru)
PT (1) PT2644206T (ru)
SI (1) SI2644206T1 (ru)
TR (1) TR201907313T4 (ru)
WO (1) WO2005000360A2 (ru)
ZA (1) ZA200505157B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855340B2 (en) 2012-10-11 2018-01-02 Ascendis Pharma A/S Hydrogel prodrugs

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
LT1596887T (lt) 2003-02-26 2022-04-25 Nektar Therapeutics Polimero-faktoriaus viii fragmento konjugatai
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
CA2549011A1 (en) 2003-12-10 2005-06-30 Nektar Therapeutics Al, Corporation Compositions comprising two different populations of polymer-active agent conjugates
EP1725262B1 (en) 2004-03-15 2021-05-26 Nektar Therapeutics Polymer-based compositions and conjugates of hiv entry inhibitors
KR101146160B1 (ko) * 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
EP1768700B1 (en) * 2004-07-16 2010-12-15 Nektar Therapeutics Conjugates comprising gm-csf and a polymer
EA200700380A1 (ru) * 2004-08-31 2007-10-26 Фармация Энд Апджон Компани Ллс Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения
MX350293B (es) 2004-11-12 2017-09-04 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
EP1848461A2 (en) 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
EP1885403B1 (en) 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
CA2604393A1 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
EP1898955A2 (en) * 2005-06-17 2008-03-19 Nektar Therapeutics AL, Corporation Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs
US8568705B2 (en) * 2005-07-18 2013-10-29 Nektar Therapeutics Method for preparing branched functionalized polymers using branched polyol cores
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
CN103030801B (zh) * 2006-02-21 2015-07-22 尼克塔治疗公司 嵌段可降解聚合物及由其制备的轭合物
ITMI20060612A1 (it) * 2006-03-30 2007-09-30 Keryos Spa New activaded poly-ethylene glycols-and related polymers and their applications
JP2009533347A (ja) 2006-04-07 2009-09-17 ネクター セラピューティックス エイエル，コーポレイション 抗ＴＮＦα抗体の複合体
US20090285780A1 (en) * 2006-05-24 2009-11-19 Chyi Lee Peg linker compounds and biologically active conjugates thereof
WO2008019214A1 (en) 2006-08-04 2008-02-14 Prolong Pharmaceuticals, Inc. Modified erythropoietin
ATE459659T1 (de) * 2006-11-07 2010-03-15 Dsm Ip Assets Bv Carbamat, thiocarbamat oder carbamid mit einer biomolekularen gruppierung
JP5347510B2 (ja) * 2007-02-05 2013-11-20 日本新薬株式会社 ポリエチレングリコール誘導体
US20140011964A1 (en) * 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
CN101631568B (zh) * 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
AU2014200906B2 (en) * 2007-03-12 2016-07-07 Nektar Therapeutics Oligomer-protease inhibitor conjugates
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
WO2009055014A2 (en) * 2007-10-23 2009-04-30 Nektar Therapeutics Al, Corporation Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
EP2222329A1 (en) * 2007-11-09 2010-09-01 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
CN101998866A (zh) 2008-04-11 2011-03-30 尼克塔治疗公司 低聚物-芳氧基-取代的丙胺共轭物
TWI421093B (zh) * 2008-07-31 2014-01-01 Pharmaessentia Corp 胜肽－聚合物綴合物
JP5588983B2 (ja) 2008-08-11 2014-09-10 ウェルズ ファーゴ バンク ナショナル アソシエイション マルチアームポリマーアルカノエートコンジュゲート
WO2010033219A2 (en) 2008-09-17 2010-03-25 Nektar Therapeutics Protease inhibitors having enhanced features
EP2340045B1 (en) 2008-09-19 2017-04-12 Nektar Therapeutics Polymer conjugates of protegrin peptides
WO2010033220A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010033224A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of kiss1 peptides
WO2010033216A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of nesiritide peptides
EP2344199A1 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
EP2334338A2 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of c-peptides
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033218A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
EP2334337A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
WO2010033205A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of v681-like peptides
US20110237524A1 (en) * 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
WO2010080720A2 (en) * 2009-01-12 2010-07-15 Nektar Therapeutics Conjugates of a lysosomal enzyme moiety and a water soluble polymer
US8785661B2 (en) 2009-05-13 2014-07-22 Nektar Therapeutics Oligome-containing pyrrolidine compounds
RU2531234C2 (ru) * 2009-06-22 2014-10-20 ВАЙЕТ ЭлЭлСи КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
SG177761A1 (en) 2009-07-31 2012-03-29 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
US9226969B2 (en) * 2009-11-18 2016-01-05 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
US8765432B2 (en) * 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP2013533217A (ja) 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
US10040761B2 (en) * 2010-06-25 2018-08-07 Nof Corporation Branched hetero polyethylene glycol and intermediate
KR20130125753A (ko) 2010-07-20 2013-11-19 할로자임, 아이엔씨 항-히알루로난제 투여와 관련된 유해 부작용의 치료
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
CA3144697A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
EP2654797B1 (en) 2010-12-23 2017-11-08 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
JP6002149B2 (ja) 2010-12-23 2016-10-05 ネクター セラピューティクス ポリマー−スニチニブコンジュゲート
WO2012088506A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-semaxanib moiety conjugates
EP2907504B1 (en) 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
BR112013032265A2 (pt) 2011-06-17 2016-12-20 Halozyme Inc métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
US20180289821A1 (en) * 2011-08-03 2018-10-11 Anp Technologies, Inc. Oxazoline Polymer Compositions and Use Thereof
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
EP2771028A2 (en) 2011-10-24 2014-09-03 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
JP6067746B2 (ja) 2011-12-30 2017-01-25 ハロザイム インコーポレイテッド Ｐｈ２０ポリペプチド変異体、その製剤および使用
JP6042527B2 (ja) 2012-04-04 2016-12-14 ハロザイム インコーポレイテッド 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
CN102643420B (zh) * 2012-05-09 2015-05-20 中国科学院过程工程研究所 一种异端基双官能团聚烷基醚类化合物及其用途
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
EP2947111B1 (en) * 2013-01-17 2018-03-07 Xiamen Sinopeg Biotech Co., Ltd. Monofunctional branched polyethyleneglycol and bio-related substance modified by same
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
SI3041513T1 (sl) 2013-09-08 2020-11-30 Kodiak Sciences Inc. Zwitterionski polimerni konjugati faktorja VIII
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
CN103980494B (zh) * 2014-04-21 2016-04-13 国家纳米科学中心 一种具有抗肿瘤活性的多肽聚合物及其制备方法和应用
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
ES2727137T3 (es) 2014-08-28 2019-10-14 Halozyme Inc Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CN107530403A (zh) 2014-11-06 2018-01-02 药华医药股份有限公司 用于长效型干扰素的剂量方案
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
MX2019015402A (es) 2017-06-22 2020-07-20 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso.
WO2019176875A1 (ja) * 2018-03-13 2019-09-19 日油株式会社 主鎖および側鎖に単分散ポリエチレングリコールを有するヘテロ二官能性化合物
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CR20200546A (es) 2018-05-21 2021-05-18 Nektar Therapeutics ESTIMULADOR SELECTIVO TREG RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS
CN112654562B (zh) * 2018-07-20 2023-06-02 赫尔克里士有限公司 水溶性或水分散性组合物
SG11202106244RA (en) 2018-12-28 2021-07-29 Catalyst Biosciences Inc Modified urokinase-type plasminogen activator polypeptides and methods of use
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
RU2699071C1 (ru) * 2019-04-16 2019-09-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "МИРЭА - Российский технологический университет" Новый полиэтиленгликольсодержащий глицеролипид
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL313567A (en) 2021-12-14 2024-08-01 Lilly Co Eli Dose transmitters for selective TREG stimulator RUR20KD-IL-2 and related preparations
CN116769159A (zh) * 2023-05-12 2023-09-19 苏州大学 一种聚芳基吡啶及其制备方法与应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856830A (en) 1971-12-23 1974-12-24 Atlas Chem Ind Polymerizable urethane compounds
US3954584A (en) 1973-06-20 1976-05-04 Kansai Paint Company Photopolymerizable vinylurethane liquid composition
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2632677A1 (de) * 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
US4180491A (en) 1976-12-01 1979-12-25 Rohm And Haas Company Nonionic polyurethane thickener with surfactant cothickener and organic diluent, clear concentrates, aqueous print pastes, coloring compositions, methods of making and printing
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5290418A (en) 1992-09-24 1994-03-01 Applied Biosystems, Inc. Viscous electrophoresis polymer medium and method
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
EP0796108A2 (en) 1994-12-06 1997-09-24 Ryan Pharmaceuticals, Inc. Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
PL185040B1 (pl) 1995-06-07 2003-02-28 Affymax Tech Nv Peptyd wiążący się z receptorami erytropoetyny, kompozycja farmaceutyczna zawierająca ten peptyd i jego zastosowanie do wytwarzania środka leczniczego
KR100404774B1 (ko) 1995-09-06 2004-04-01 아사히 덴카 고교 가부시키가이샤 점성조정제
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
UA65549C2 (ru) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Применение аналогов и производных glp-1 для периферического введения для борьбы с ожирением
CA2299425A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU1325400A (en) * 1998-10-26 2000-05-15 University Of Utah Research Foundation Method for preparation of polyethylene glycol aldehyde derivatives
CA2376057A1 (en) 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
KR100758158B1 (ko) * 1999-07-14 2007-09-12 알자 코포레이션 중성 지질중합체 및 그를 함유하는 리포솜 조성물
EP1192182B1 (en) 1999-09-28 2008-06-04 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
EP1259563B2 (en) 1999-12-22 2016-08-10 Nektar Therapeutics Method for the preparation of 1-benzotriazolyl carbonate esters of water soluble polymers.
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
JP2002003604A (ja) * 2000-06-21 2002-01-09 Sanyo Chem Ind Ltd 樹脂改質剤
KR100396983B1 (ko) * 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
DE60236796D1 (de) 2001-01-30 2010-08-05 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
DE10114134A1 (de) 2001-03-19 2002-11-28 Biogenes Verfahren zur Herstellung modifizierter Hydroxypolymere mit einer oder mehreren funktionellen Gruppen und deren Verwendung
US7041855B2 (en) * 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
DE60326224D1 (de) 2002-04-26 2009-04-02 Solexa Inc Signaturen konstanter länge für das parallele sequenzieren von polynukleotiden
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
AU2003295433A1 (en) 2002-11-12 2004-06-03 Enzon Pharmaceuticals, Inc. Branched polymeric prodrugs of vancomycin
US7217845B2 (en) * 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
LT1596887T (lt) * 2003-02-26 2022-04-25 Nektar Therapeutics Polimero-faktoriaus viii fragmento konjugatai
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
KR102612902B1 (ko) 2016-04-22 2023-12-18 삼성디스플레이 주식회사 투명 전도막 및 이를 포함하는 전자 소자

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855340B2 (en) 2012-10-11 2018-01-02 Ascendis Pharma A/S Hydrogel prodrugs
RU2647729C2 (ru) * 2012-10-11 2018-03-19 Асцендис Фарма Ас Пролекарства на основе гидрогеля

Also Published As

Publication number Publication date
ZA200505157B (en) 2006-05-31
EA011351B1 (ru) 2009-02-27
US7887789B2 (en) 2011-02-15
CN1747748B (zh) 2011-01-19
IL169165A (en) 2011-02-28
CA2510040A1 (en) 2005-01-06
WO2005000360A3 (en) 2005-07-28
PL2644206T3 (pl) 2019-09-30
KR101128320B1 (ko) 2012-04-12
CN1747748A (zh) 2006-03-15
SI2644206T1 (sl) 2019-06-28
EP2644206A2 (en) 2013-10-02
CA2510040C (en) 2012-01-03
JP2007500278A (ja) 2007-01-11
EP3593820A1 (en) 2020-01-15
ES2725808T3 (es) 2019-09-27
NZ541374A (en) 2008-09-26
AU2004251602A1 (en) 2005-01-06
DK2644206T3 (da) 2019-06-11
WO2005000360A2 (en) 2005-01-06
LT2644206T (lt) 2019-05-27
EP2644206A3 (en) 2014-04-16
EP2644206B1 (en) 2019-04-03
PT2644206T (pt) 2019-07-10
KR20060026845A (ko) 2006-03-24
MXPA05007628A (es) 2005-10-19
EP1626741A2 (en) 2006-02-22
CY1121759T1 (el) 2020-07-31
HUE043911T2 (hu) 2019-09-30
JP5048332B2 (ja) 2012-10-17
AU2004251602B2 (en) 2010-05-13
US20050009988A1 (en) 2005-01-13
IL169165A0 (en) 2007-07-04
TR201907313T4 (tr) 2019-06-21

Similar Documents

Publication Publication Date Title
EA200501863A1 (ru) Полимерные производные, имеющие специфические атомные структуры
MXPA05007165A (es) Reactivos polimericos que comprnden una cetona o un grupo funcional relacionado.
CY2019029I1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
BR0207378A (pt) Tratamento de câncer
DE60231749D1 (de) Supercharge-nachrichtenaustauschvorrichtung
AU2001291687A1 (en) Polyammonium-polysiloxane compounds, methods for the production and use thereof
BR0114646A (pt) anticorpos anti-lt-beta-r humanizados
DE60010098D1 (de) 28-epirapaloge
FR11C0053I2 (fr) Molecules ctla4 mutantes solubles et leurs utilisations
AR022963A1 (es) Vacuna
WO2006069388A3 (en) Stabilized polymeric thiol reagents
ATE431412T1 (de) Antikörper gegen il-12, zusammensetzungen, verfahren und verwendungen
BRPI0405450A (pt) Agente de revestimento
ATE283328T1 (de) Gefrierschutzmittelkonzentrate enthaltend den farbstoff c.i. reactive violet 5
DE50102093D1 (de) Polymerblends
PT1140808E (pt) Formulacoes de pesticidas contendo tensioactivos de ester de hemissulfato de tristirilfenol alcoxilado, neutralizados com amina alcoxilada
WO2002096367A3 (en) Targeted multivalent macromolecules
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
DE59913099D1 (de) Wässrige, pigmenthaltige polymerzubereitungen
RS51478B (sr) Upotreba bradikardijskih supstanci u lečenju miokardnih oboljenja povezanih sa hipertrofijom i nove kombinacije lekova
DE60032962D1 (de) Breitbandiger Hochleistungswanderfeldphotodetektor
NO20030536D0 (no) Polymer elektrolyttsammensetning
DE60131121D1 (de) Wasserlösliches Copolymer, Verfahren zu dessen Herstellung und dessen Verwendung
FR2833610B1 (fr) Construits cellulaires cultives in vitro, preparation et utilisations
BR0110577A (pt) Decorina transgenicamente produzida

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title